Polyrizon Ltd., a pre-clinical-stage biotechnology company, announced positive results from a new in-vitro pre-clinical study evaluating its PL-14 Allergy Blocker formulation. The study assessed PL-14's ability to block the transfer of Der p 1, a major house dust mite allergen, in a validated laboratory model simulating nasal tissue. Results showed that PL-14 significantly outperformed hydroxypropyl methylcellulose (HPMC), a standard nasal barrier comparator, by maintaining much lower allergen permeation at all tested time points. PL-14 achieved a maximum mean allergen level of approximately 141.2 ng at 4 hours, compared to HPMC's 5201.2 ng at 24 hours. Polyrizon plans to use these findings to support future clinical studies aimed at establishing PL-14's regulatory pathway and clinical benefits for allergy prevention. The company did not specify if or when these results will be presented at a scientific meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9619711-en) on January 05, 2026, and is solely responsible for the information contained therein.